aMoon Fund

Exciting News from Air Doctor -  we've secured $20M in Series B funding! 👏👏👏 Led by aMoon Fund and supported by key industry players like Tokio Marine Group, Samsung Ventures (SVIC), and current shareholders Lightspeed Venture Partners, Vintage Investment Partners, Phoenix Insurance, and Munich Re Ventures. This investment accelerates our global expansion, enhancing our ability to offer seamless healthcare experiences for travelers across 84 countries (and counting). Above all, it solidifies our position as a leader in travel healthcare. We're proud of how far we’ve come, and we’re excited for what’s next. Together, we're setting a new market standard in global healthcare access. 🌍 Read it here: https://lnkd.in/eZFE7V2c #GlobalExpansion #InsurancePartners #B2B #SeriesB #TravelHealthcare #Insurance #InsurTech #Innovation

For the Hebrew New Year, here is an exciting open position ! Coltac Therapeutics, a stealth-mode VC-backed startup focused on the cutting-edge field of molecular glues, is seeking a highly motivated and skilled Head of Computational Drug Discovery. For the full job description, click here https://lnkd.in/dbjinuPy To apply please send your updated CV to [email protected] aMoon Fund, Israel Biotech Fund

Big thanks to everyone from the #biotech and #research sectors who attended the pitch event at Ovolo South Yarra this week – this was the final workshop of the WEHI-Baker Institute aMoon Innovation Fellows Program. I’m sure you will agree there were some exciting scientific projects and translation pathways showcased. Guest speakers included Dr Yaron Daniely, General Partner and Head at aMoon, a global HealthTech and Life Sciences investment fund based in Israel. Dr Daniely was formerly President and CEO of Yissum, Hebrew University’s Technology Transfer Company, and Co-Chairperson of the Israel Technology Transfer Network. And a special shout out to our host, the Baker Institute’s Executive GM of Commercialisation, Dr Guy Krippner. Hats off to researchers from the Olivia Newton-John Cancer Research Institute, Burnet Institute and the Baker Heart and Diabetes Institute for pitching their innovative projects, and to all the Institutes who had participants take part in the program including Murdoch Children's Research Institute (MCRI), Hudson Institute of Medical Research, St Vincent's Institute of Medical Research and WEHI (Walter and Eliza Hall Institute of Medical Research). This is the third aMoon Innovation Fellows Program which started at the Baker Institute, with the content primarily delivered by aMoon as well as local commercialisation experts. Jumar Bioincubator FB Rice Brandon Capital MTPConnect PAN Group BioCurate Pty Ltd Double Helix Investment Corp Tin Alley Ventures Association of Australian Medical Research Institutes (AAMRI) Newburyport Partners CSIRO Hon. Jaala Pulford Heidi Roache Anna Tran

Today we are honored to announce a global license agreement with Immunome, Inc. Under the terms of the license, Immunome received exclusive rights to a panel of antibodies targeting a novel undisclosed target. “This agreement allows Nectin Therapeutics to realize value while further pursuing and enabling the focus on our first-in-class anti-PVR program (NTX1088) through its ongoing clinical study in tumor types with high unmet need, in parallel to advancing our novel #ADCs into clinical development. Immunome’s leadership team’s track record of developing and commercializing novel ADC therapies makes it an ideal partner to advance these promising assets,” said Fabian Tenenbaum, Chief Executive Officer of Nectin Therapeutics. “Immunome believes the next generation of transformative antibody-drug conjugates will address novel targets by pairing high-quality antibodies with innovative linker-payload technology,” said Clay Siegall, PhD, President and Chief Executive Officer of Immunome. “We appreciate the work Nectin has done on these antibodies and look forward to advancing them further.” To read about the news: https://lnkd.in/g68U9GBf #CancerResearch #Immunotherapy #Biotechnology

We are thrilled to be collaborating with Labcorp to help transform oncology testing. Ultima’s high throughput, low cost sequencing architecture combined with our ability to be accurate at extremely low limits of detection with ppmSeq aims to drive increased efficiency and scalability while improving access to affordable genetic testing.    Read more here: https://lnkd.in/gSR2qMja   #NGS #ppmSeq #oncologytesting